Dacarbazine
- Atc Codes:L01AX04
- CAS Codes:4342-03-4
- PHARMGKB ID:4342-03-4
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Substrate of
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Dacarbazin, Dacarbazine; Belgium: Dacarbazine; Cyprus: Dacarbazine; Czech Republic: Dacarbazin; Denmark: Dacarbazine; Finland: Dacatic; France: Dacarbazine, Deticene; Germany: D.T.I.C., Detimedac; Greece: Dacarbazine, Deticene; Hungary: Dacarbazin; Ireland: Dacarbazine; Lithuania: Dacarbazin; Malta: Dacarbazine; Netherlands: Deticene; Poland: Dacarbazin; Portugal: Dacarbazina, Deticene, Fauldetic; Slovakia: Dacarbazin; Spain: Dacarbazina; Sweden: Dacarbazine; UK: Dacarbazine.
North America
Canada: Dacarbazine; USA: Dacarbazine, DTIC.
Latin America
Argentina: Dacarbazina, Oncocarbil; Brazil: Baxcarbas, Dacarb, Evodazin; Mexico: Detilem.
Asia
Japan: Dacarbazine.
Drug combinations
Dacarbazine, Carmustine, and Cisplatin
Dacarbazine, Cisplatin, and Vinblastine
Dacarbazine, Aldesleukin, Cisplatin, and Interferon Alpha-2b
Dacarbazine, Carmustine, Cisplatin, and Tamoxifen
Chemistry
Dacarbazine: C~6~H~10~N~6~O. Mw: 182.18. (1) 1H-Imidazole-4-carboxamide, 5-(3,3-dimethyl-1-triazenyl)-; (2) 5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide. CAS-4342-03-4 (1972).
Pharmacologic Category
Antineoplastic Agents; Alkylating Agents; Triazene. (ATC-Code: L01AX04).
Mechanism of action
Alkylating agent which appears to form methylcarbonium ions which attack nucleophilic groups in DNA, and cross-link strands of DNA, resulting in the inhibition of DNA, RNA, and protein synthesis.
Therapeutic use
Treatment of malignant melanoma, Hodgkin’s disease, soft-tissue sarcomas, fibrosarcomas, rhabdomyosarcoma, islet cell carcinoma, medullary carcinoma of the thyroid, and neuroblastoma.
Pregnancy and lactiation implications
Carcinogenic and/or teratogenic in animals. Should not be used in the 2^nd^ or 3^rd^ trimester of pregnancy. Breast-feeding is not recommended.
Unlabeled use
Contraindications
Hypersensitivity to dacarbazine or any component of the formulation.
Warnings and precautions
Anaphylaxis may occur. Bone marrow suppression is common. May be carcinogenic and/or teratogenic. Hepatotoxicity with hepatocellular necrosis and hepatic vein thrombosis reported. Caution in hepatic/renal impairment (half-life is increased). Rapid I.V. infusion may cause severe venous irritation.